Chronic lymphocytic leukaemia(CLL)has one of the strongest familial risks of all cancers,as evidenced by the eight-fold increased risk seen in relatives of CLL patients,yet much of the heritable risk remains unexplain...Chronic lymphocytic leukaemia(CLL)has one of the strongest familial risks of all cancers,as evidenced by the eight-fold increased risk seen in relatives of CLL patients,yet much of the heritable risk remains unexplained[1].Patients with CLL also have a high rate of secondary cancer,i.e.,the development of second primary malignancy,compared to the general population,which may be explained by immune dysregulation due to CLL and/or its treatment,but also by environmental and genetic risk factors[2].The development of second cancer in patients with CLL contributes to higher morbidity in these patients[2].As the population of long-term CLL survivors expands due to novel agents used in therapy,the identification of patients with risk of developing the second cancer may help to improve longevity of CLL patients.展开更多
基金supported by the project JG_2024_035 implemented within the PalackýUniversity Young Researcher Grantby the Internal grant agency of Palacky University(IGA_LF_2025_014)in part by Ministry of Health of Czech Republic(MH CZ-DRO(FNOL,00098892)).
文摘Chronic lymphocytic leukaemia(CLL)has one of the strongest familial risks of all cancers,as evidenced by the eight-fold increased risk seen in relatives of CLL patients,yet much of the heritable risk remains unexplained[1].Patients with CLL also have a high rate of secondary cancer,i.e.,the development of second primary malignancy,compared to the general population,which may be explained by immune dysregulation due to CLL and/or its treatment,but also by environmental and genetic risk factors[2].The development of second cancer in patients with CLL contributes to higher morbidity in these patients[2].As the population of long-term CLL survivors expands due to novel agents used in therapy,the identification of patients with risk of developing the second cancer may help to improve longevity of CLL patients.
